DNA

GINKGO BIOWORKS HOLDINGS INC

Healthcare | Small Cap

-$0.60

EPS Forecast

$20.65

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

DNA’s Dual-Lab Bet: Ginkgo Bioworks’ Q3 2026 Update Keeps Nebula in Play While Livens Up the Burn

Executive snapshot

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) reported third-quarter 2026 results anchored by its two-pronged platform: Autonomous Labs equipment (RAC + Catalyst) and Cloud Lab Services. The press release, issued November 5, 2026 from Boston, emphasizes progress on commercial deployments and government collaborations alongside a continued cash burn, with a revenue line near the low-$30s or low-$20s if you round, but actual quarterly revenue stood at $28 million for Q3 2026. On the profitability front, GAAP net loss from continuing operations narrowed to $(41) million from $(73) million a year ago, and Adjusted EBITDA improved to $(22) million from $(53) million in the prior-year quarter. The company ended September 30, 2026 with $285 million in cash, cash equivalents and marketable securities, and a cash burn of about $27 million in the quarter.

For investors scanning the earnings tape, the report provides EPS framing via GAAP loss and the lack of a disclosed EPS figure in the release. There is no stated EPS consensus or explicit earnings surprise in the material. Nor is there a forward-looking revenue forecast in the press release, leaving some questions about near-term growth cadence despite the government and enterprise momentum.

Financials at a glance

  • Third-quarter revenue: $28 million, down 6% from $29 million in the year-ago quarter; sequentially up from $20 million in Q2 2026.
  • GAAP net loss from continuing operations: $(41) million vs $(73) million a year earlier.
  • Adjusted EBITDA: $(22) million, an improvement from $(53) million in the prior-year period.
  • Liquidity: cash, cash equivalents and marketable securities of $285 million as of September 30, 2026.
  • Cash burn in the quarter: approximately $27 million.

Two offerings, one platform: Autonomous Labs and Cloud Lab Services

The company reiterates a dual-stream model built on the Nebula platform. Autonomous Labs Equipment—the RAC (reconfigurable autonomous carts) and Catalyst systems—targets pharma, national labs, universities and government customers, including Novo. Cloud Lab Services leverage Nebula to run ADME, DRUG-seq and antibody data generation for pharma, while also supplying AI training data for frontier labs and tech-bio outfits.

Management frames this as a long-run capability: “Autonomous Labs and Cloud Lab” are not just product buckets; they are a unified platform strategy positioning Ginkgo as a lab infrastructure provider rather than a one-off service vendor. The revenue cadence today looks more like deployment and service ARR ramps rather than a rapid-margin climb; the press release emphasizes ongoing deals and government-backed projects as the fuel for future growth.

Policy tailwinds and government collaborations

A central theme is the government’s embrace of autonomous lab infrastructure. Ginkgo highlights Novo’s autonomous-lab sale at Novo’s R&D site in Waltham, MA, alongside grant and contract activity with ARPA-H and the NSF. The firm notes that Nebula underpins onshore experiments, reducing reliance on overseas CROs and expanding data-generation capabilities for both drug development and AI-training datasets.

Beyond individual deals, the narrative points to the Genesis Mission and the NSF’s Programmable Cloud Laboratories (PCL) initiative, plus a White House OSTP acknowledgement on October 8. The implication is that autonomous-lab platforms may be treated as national infrastructure—a potential tailwind for long-horizon contracts and large-scale system deployments, not just point-solution sales. The company also cites collaborations with Caltech, University of Maryland and Northwestern under the NSF’s PCL Test Bed, and MIT Media Lab’s RAC-based cloud-lab work—infra projects with reputational and capability-value spillovers.

What this might portend for DNA and its peers

A key takeaway is rhythm, not rocket ships: Ginkgo’s Q3 results show dialing back the quarterly revenue pace while maintaining a longer arc that favors platform leverage. The cash burn remains meaningful, even as management touts improving profitability metrics on a GAAP basis and better Adjusted EBITDA versus last year. For DNA, the immediate market implication isn't a quick flip to profitability; it's whether the two-pronged platform can translate autonomous-lab deployments and Nebula-driven data services into durable recurring revenue or multi-year government contracts with predictable budgets.

For sector peers, the message is twofold. First, policy and national infrastructure programs could underpin demand for lab automation and data generation, particularly if Nebula-like platforms achieve broader adoption across pharma and bioscience customers. Second, the emphasis on large-customer deals (e.g., Novo) and government programs may reward players who can scale out a robust installed base and sustain high-capex cycles, rather than firms that rely on sporadic project work.

Analyst view and investor takeaways

The absence of a reported EPS figure in the release means investors must interpolate between GAAP losses and negative Adjusted EBITDA to gauge near-term earnings power. The EPS consensus for DNA remains a point of curiosity for many analysts, as the quarter does not publish per-share metrics. The revenue forecast for 2026 remains unclear in the document, raising questions about how the company expects to scale from the Q3 base.

Yet the narrative of two linked offerings on a single platform—Autonomous Labs and Cloud Lab Services—could become a strategic advantage if DNA can convert government and enterprise pilots into durable revenue streams. The Novo contract and ARPA-H/NSF wins are the kinds of big-ticket, multi-year engagements that can help flatten cash burn as the company moves toward scale. In the meantime, $285 million of liquidity provides a cushion for ongoing investment in Nebula and the equipment line, even as quarterly revenue remains modest.

Takeaways

  • DNA’s Q3 2026 shows progress in narrowing losses and improving cash burn alongside steady revenue in a low-growth quarter.
  • The two-offering model—Autonomous Labs Equipment and Cloud Lab Services—continues to be pitched as a unified platform with Nebula at the core.
  • Government and large enterprise partnerships (Novo, ARPA-H, NSF, Genesis Mission) are the focal points for near-term deal flow and potential revenue visibility.
  • Liquidity remains robust for the era of multi-year lab-infrastructure deployments, even as the quarterly revenue forecast and EPS consensus remain uncertain in the press release.
  • For peers, the story is less about a quick margin expansion and more about platform leverage, installed-base expansion, and the ability to monetize data generated on Nebula at scale.

Note: This summary reflects the third-quarter 2026 results press release from Ginkgo Bioworks Holdings, Inc. Readers should consider full-year guidance, non-GAAP adjustments, and conference-call commentary for a complete view. The company’s ticker is DNA, and the quarter under discussion ended September 30, 2026.